Table 2.

Patient and sample characteristics^*

Patient	Diagnosis	Number of samplesa	DNA, ng/µlb	First indication of recipient chimerism, days post HSCT		Evidence for relapsec	Comment
				STR-PCR	indel-qPCR
1	AML	6	3–475	1,273	1,273	thrombocyte count ↓, blasts (BM/PB)
2	AML	11	9–176	208/569	208/569	DEK-CAN fusion ↑, blasts(BM/PB)	2× RL
3	AML	8	10–172	853/1,105	231/1,008	thrombocyte count ↓, blasts (BM)	2× RL
4	ALL	11	12–128	126/716	126/716	blasts (BM/PB)	2× RL, †
5	AML	10	6–64	32/314	32/314	blasts (BM/PB)
6	AML	2	5–61	97	97	blasts (BM)	†
7	MM	5	29–108	–	423	clonal IgG ↑
8	MM	3	19–46	–	111	serum κ-chains ↑	†
9	ALL	3	3–250	105	105	blasts (PB)	†
10	MM	4	15–50	185	185	clonal IgG ↑, plasma cell expansion (BM)	†
11	NHL	5	10–189	29	29	residual lymphoma	stable MC
12	ALL	3	35–220	230	54	BCR-ABL+ after HSCT
13	MM	5	18–238	243	148	clonal IgG ↑, plasma cell expansion (BM)	HID
14	NHL	6	20–105	41	41	incompl. donor hematopoiesis	HID, stable MC
15	ALL	4	35–259	86	36	blasts (BM)
16	NHL	3	23–242	62	35	blasts (PB)

AML = Acute myeloid leukemia; ALL = acute lymphoblastic leukemia; BM = bone marrow; HID = HLA-identical sibling donor; MC, mixed chimerism; MM = multiple myeloma; NHL= non-Hodgkin's lymphoma; PB = peripheral blood; STR = short-tandem-repeat; indel = micro insertion/deletion. polymorphism

^†= deceased.

^*Cases where indel-qPCR provided an earlier detection of recipient chimerism are highlighted in italics.

^aNumber of post HSCT samples available for retrospective analysis by indel-qPCR.

^bDNA concentration range of the samples, 100μl of each sample were available in most cases.

^cMolecular and cytological evidence for relapse.